CDK4/6 inhibition triggers anti-tumour immunity

Nature

Volumn 548, Issue 7668, 2017, Pages 471-475

  Goel, Shom ^a   Decristo, Molly J ^b,c   Watt, April C ^a   Brinjones, Haley ^a   Sceneay, Jaclyn ^b,c   Li, Ben B ^a   Khan, Naveed ^a   Ubellacker, Jessalyn M ^b,c   Xie, Shaozhen ^a   Metzger Filho, Otto ^a   Hoog, Jeremy ^d   Ellis, Matthew J ^e   Ma, Cynthia X ^d   Ramm, Susanne ^b,c   Krop, Ian E ^a   Winer, Eric P ^a   Roberts, Thomas M ^a   Kim, Hye Jung ^a,b   McAllister, Sandra S ^b,c,f,g   Zhao, Jean J ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f HARVARD STEM CELL INSTITUTE   (United States)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DMAP1 PROTEIN, HUMAN; DOUBLE STRANDED RNA; INTERFERON; PROTEIN KINASE INHIBITOR; REPRESSOR PROTEIN; TRANSCRIPTOME;

ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIGEN PRESENTATION; BIOLOGICAL MIMICRY; BIOSYNTHESIS; BREAST TUMOR; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VIRUS;

ANIMALS; ANTIGEN PRESENTATION; BIOLOGICAL MIMICRY; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTERFERONS; MICE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; REPRESSOR PROTEINS; RNA, DOUBLE-STRANDED; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TRANSCRIPTOME; VIRUSES;

EID: 85028340229     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature23465     Document Type: Article

References (30)

1. Yu, Q. et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9, 23-32 (2006).
2. Choi, Y. J. et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell 22, 438-451 (2012).
3. Patnaik, A. et al. Efcacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 6, 740-753 (2016).
4. Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375, 1925-1936 (2016).
5. Sherr, C. J. & Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512 (1999).
6. Goel, S. et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell 29, 255-269 (2016).
7. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
8. Campisi, J. & d'Adda di Fagagna, F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8, 729-740 (2007).
9. Ma, C. X. et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin. Cancer Res. (2017).
10. Roulois, D. et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961-973 (2015).
11. Kimura, H., Nakamura, T., Ogawa, T., Tanaka, S. & Shiota, K. Transcription of mouse DNA methyltransferase 1 (Dnmt1) is regulated by both E2F-Rb-HDAC-dependent and-independent pathways. Nucleic Acids Res. 31, 3101-3113 (2003).
12. Chiappinelli, K. B. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162, 974-986 (2015).
13. Coppé, J. P., Desprez, P. Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99-118 (2010).
14. Malumbres, M. et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118, 493-504 (2004).
15. Obata, Y. et al. The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells. Nat. Immunol. 15, 571-579 (2014).
16. Reg interactions with intratumoral APCs promote local CTL dysfunction. J. Clin. Invest. 124, 2425-2440 (2014).
17. Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187-2194 (2010).
18. Finn, R. S. et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11, R77 (2009).
19. Heng, T. S. et al. The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. 9, 1091-1094 (2008).
20. Bates, G. J. et al. Quantifcation of regulatory T cells enables the identifcation of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24, 5373-5380 (2006).
21. McAllister, S. S. et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 133, 994-1005 (2008).
22. Wong, C. S. et al. Vascular normalization by loss of Siah2 results in increased chemotherapeutic efcacy. Cancer Res. 72, 1694-1704 (2012).
23. Bellone, M. et al. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J. Immunol. 165, 2651-2656 (2000).
24. Ni, J. et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat. Med. 22, 723-726 (2016).
25. Wang, Y. et al. CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell 163, 174-186 (2015).
26. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
27. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
28. Mootha, V. K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267-273 (2003).
29. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
30. Gimenez, J. et al. Comparative methylation of ERVWE1/syncytin-1 and other human endogenous retrovirus LTRs in placenta tissues. DNA Res. 16, 195-211 (2009).